research 24 ARQ-234: a high affinity CD200-Fc fusion protein for the treatment of atopic dermatitis
ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.
Search
for
Sort by
Research
870-900 / 1000+ results 
research Plants Producing Ribosome-Inactivating Proteins in Traditional Medicine
Some plants used in traditional medicine may help treat cancer because they contain proteins that can inactivate ribosomes.
research Axitinib-induced repigmentation of grey hair in a patient with metastatic renal cell carcinoma
Axitinib treatment turned a man's grey hair back to black.
research 557 Short-term Rho-associated kinase inhibitor treatment accelerates primary keratinocyte growth without affecting the characteristics of the stem cell population
Short-term treatment with ROCKi increases skin cell growth without changing stem cell features.
research Enzalutamide/finasteride/goserelin/zoledronic-acid
research Perifolliculitis capitis abscedens et suffodiens treatment with tumor necrosis factor inhibitors and baricitinib: A case report and literature review
A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.
research An urticarial drug eruption caused by tofacitinib for alopecia universalis
A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.
research Adjunctive Dupilumab Therapy in a Partial Responder to Baricitinib for Alopecia Areata
Adding dupilumab led to almost complete hair regrowth in a patient with alopecia areata who only partially responded to baricitinib.
research Clinical Application of Development of Nonantibiotic Macrolides That Correct Inflammation-Driven Immune Dysfunction in Inflammatory Skin Diseases
Nonantibiotic macrolides show promise for treating various inflammatory skin conditions.
research 491 Efficacy of oral tofacitinib in the treatment of lichen planopilaris
Oral tofacitinib significantly improves lichen planopilaris symptoms without adverse effects.
research Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts
Steroidogenesis inhibitors change but don't stop androgen production in prostate cancer.
research Topical tacrolimus suppresses the expression of vascular endothelial growth factor and insulin-like growth factor-1 in late anagen
Topical tacrolimus reduces certain growth factors in hair follicles.
research Systemic Absorption and Pharmacokinetics of Five Novel Topical Dermatologic Agents: A Review
These new skin treatments are safer and more effective with minimal side effects.
research In vivo and in vitro effect of novel 4,16-pregnadiene-6,20-dione derivatives, as 5α-reductase inhibitors
The new compounds may be more effective and cheaper than current treatments for conditions like baldness.
research Hair regrowth in a patient with central centrifugal cicatricial alopecia after a 2-month trial of baricitinib
A woman with a type of hair loss saw hair regrowth after two months of taking baricitinib.
research Experimental Assessment of 3-<i>meta</i>-Pyridine-1,2,4-Oxadiazole Deoxycholic Acid Derivative as a Prototype of 5-α-Reductase Inhibitors <i>in silico</i> and <i>in vivo</i> Models
The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.
research AB0597 Comparative analysis of safety data of four treatment regimens in early rheumatoid arthritis patients
Methotrexate plus prednisolone had the fewest serious side effects.
research Alopecia Areata – Effects of Treatment with Upadacitinib – Two Case Reports
Upadacitinib can effectively regrow hair in alopecia areata patients without worsening sarcoidosis.
research PD23-01 INHIBITOR OF 5A-REDUCTASE TYPES II PROMOTES THE INFILTRATION OF CD8+T CELLS IN BPH TISSUES.
Finasteride increases CD8+ T cells in BPH tissues.
research Recovery of nail dystrophy potential new therapeutic indication of tofacitinib
Tofacitinib may help treat nail dystrophy, especially when other treatments fail.
research Palmoplantar pustulosis–like eruption following tofacitinib therapy for juvenile idiopathic arthritis
Tofacitinib can cause skin eruptions similar to palmoplantar pustulosis.
research Hair-cycle changes in two patients taking tocilizumab
Tocilizumab treatment was associated with significant hair regrowth in one patient and temporary hair loss followed by regrowth in another.
research Long‐Term Real‐World Outcomes of Baricitinib in Severe Alopecia Areata: A 104‐Week Retrospective Analysis From a Single Institute
Baricitinib is effective and safe for long-term treatment of severe alopecia areata.
research Alopecia areata in a patient with psoriatic arthritis and C rohn's disease receiving etanercept
Etanercept improved arthritis and psoriasis but caused hair loss, which healed after switching to sulfasalazine.
research Impact of epidermal growth factor receptor and mitogen-activated kinase inhibition on hair follicles (HFs): partial HF immune privilege collapse and excessive interleukin-33 secretion
Inhibiting certain proteins harms hair follicle immunity and increases IL-33, affecting hair health.
![Activity of 17β-(N-Alkyl/Arylformamido) and 17β-[(N-Alkyl/Aryl) Alkyl/Arylamido]-4-Methyl-4-Aza-5α-Androstan-3-Ones as 5α-Reductase Inhibitors in the Hamster Flank Organ and Ear](/images/research/861159f1-7bd4-420c-a16b-4829458efe68/small/15592.jpg)
research Activity of 17β-(N-Alkyl/arylformamido) and 17β-[(N-Alkyl/aryl) alkyl/arylamido]-4-methyl-4-aza-5α-androstan-3-ones as 5α-Reductase Inhibitors in the Hamster Flank Organ and Ear11The research has been supported by Endorecherche that is seeking patent protection for the new compounds. F. Labrie is President of Endorecherche.
The compounds tested could potentially treat hair loss and alopecia.
research BH15 Efficacy and safety of baricitinib in the management of severe alopecia areata over a 6-month period: a real-world experience
Baricitinib was effective and safe for severe hair loss treatment over 6 months.
research 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
research Identification of compound heterozygous mutations in AP1B1 leading to the newly described recessive keratitis–ichthyosis–deafness (KIDAR) syndrome
Mutations in the AP1B1 gene cause a new syndrome with skin, hearing, and developmental issues.
research Sustained hair regrowth with ritlecitinib to Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study
Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.